

REMARKS

Entry of the above amendments and examination of the application are respectfully requested.

In response to the restriction requirement mailed January 22, 2009, Applicant hereby elects, without traverse, Species VI: Fig. 8-9. Claims 27-30, 32-37, 40-41, 45-52, 55-58 and 61-62 encompass at least the elected species.

Upon entry of the above amendment, the status of the claims will be as follows:

Claims 27-30, 32-37, 40-41, 45-52, 55-58 and 61-62 will be pending and under consideration.

Claims 31, 42-44, 53-54, 59-60 and 63-67 will have been withdrawn.

Claims 1-26, and 38-39 will have been cancelled.

As stated in Applicant's previous Office Action response (submitted on October 10, 2008), claims 45-67 are patentable and are supported by the original disclosure. Thus, no new matter has been added by way of these amendments. As to patentability relative to the cited references, each of these new claims requires the inserted embolization device to fill the blood vessel or aneurysm, cause embolus, and in the case of a blood vessel, to fully occlude. This is a dramatic contrast to the features of a stent device that holds vessels open, as discussed in Babbs et al. Further, support for claims 45-67 includes the following.

There is much discussion in the application about preparing and using embolization devices that are free from any metallic component, as well as about devices that include a metallic component. Implanting a device that is free from any metallic component so as to leave behind an all natural blockage is disclosed, for example, in paragraph [0100].

Using a thrombogenic collagenous biomaterial that is harvested from animal tissue and contains at least one biotrophic agent selected from a proteoglycan, a growth factor, a glycoprotein, and a glycosaminoglycan is disclosed, for example, in paragraph [0013]. Biomaterial sheets are disclosed, for example, in paragraph [0086].

Delivering an embolization device to a blood vessel or an aneurysm is discussed throughout the application. Delivery via a delivery catheter is disclosed, for example, in paragraphs [0089] and [0095]. Filling a blood vessel or aneurysm is disclosed, for example, in paragraph [0085] and original claim 25. Causing formation of an embolus is disclosed throughout the specification including, for example, in the Abstract and paragraph [0086]. Using thrombogenic materials to promote the formation of thrombus is disclosed throughout the specification. Causing a full occlusion is disclosed, for example, in paragraph [0086].

A thrombogenic collagenous biomaterial being biodegradable and promoting a healing response in the patient so as to result in an all natural blockage of a blood vessel is disclosed, for example, in paragraphs [0012], [0068] and [0100].

A thrombogenic collagenous biomaterial comprising submucosa, pericardium, basement membrane, or amniotic membrane is disclosed, for example, in paragraph [0013].

A thrombogenic collagenous biomaterial sheet or a thrombogenic component promoting a healing response in the patient so as to result in tissue ingrowth into an area of the blood vessel into which the embolization device is delivered is disclosed, for example, in paragraphs [0011] and [0012].

A thrombogenic component prepared from a thrombogenic collagenous biomaterial sheet, wherein the component is a comminuted component, a branched component, a helical

component, a spherical component, a cubic component, or a cylindrical component is disclosed, for example, in paragraph [0086].

Incorporating a metallic backbone to which a collagenous biomaterial is attached is disclosed, for example, in paragraph [0100].


A thrombogenic collagenous biomaterial also comprising a radiopaque substance is disclosed, for example, in paragraphs [0013] and [0086].

Additional support for claims 45-67 can be found throughout the specification and drawings.

Entry of the above-made amendment and favorable consideration of this application are requested. If the Examiner should have any questions regarding this election or other comments or suggestions to help speed the prosecution of this application, the Examiner is requested to contact the applicants' undersigned representative by telephone.

Respectfully submitted,

By



Timothy B. Paul, Reg. No. 51203
Woodard, Emhardt, Moriarty, McNett & Henry LLP
111 Monument Circle, Suite 3700
Indianapolis, Indiana 46204-5137
Telephone (317) 634-3456 Fax (317) 637-7561
Email: tpaul@uspatent.com